www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion Innovations receives further funding, DataTern signs more licensing deals worth US$4.15 mln
Medical and technology business investor Amphion Innovations PLC (AIM: AMP) said it has received a further subscription of £1.1 million for the convertible promissory note first announced in December 2008, bringing the total amount issued to £4.83 million.
Amphion also announced that its wholly owned subsidiary DataTern Inc has signed additional non-exclusive intellectual property license agreements with eight “leading international corporations” for a total of US$4.15 million.
DataTern has signed 18 licenses since it commenced licensing its product in June 2008, generating total revenues of approximately US$13 million. DataTern has now licensed its intellectual property into the financial, credit card, insurance, retail, leisure, healthcare, airline, e-commerce, and software industries.
DataTern was established in order to commercialise selected intellectual property opportunities in partnership with Amphion's partner companies.
Amphion CEO Richard Morgan said: "We are pleased to announce the continued success of our licensing programme. DataTern has signed a total of 15 agreements for approximately US$7.6 million over the course of 2009 and we are optimistic we will achieve a similar level of business in the coming year."
Amphion builds shareholder value in high growth companies in the medical and technology sectors by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
It does not invest in speculative technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least US$1 billion in size. Each partner company is chosen with the goal of achieving an exit valuation in excess of US$100 million.
Amphion’s investments also include 38.5 percent in Motif Biosciences, a 19.99 percent stake in Kromek, 20 percent in Myconostica Ltd, 15.3 percent in Firestar Software, 8.5 percent in Axcess International, 38.5 percent in Motif Biosciences, 50 percent in MSA Holdings B.S.C., 24.4 percent in M2M Imaging Corp and 25 percent in Private Markets.
